In a significant development, pharmaceutical giant Pfizer has reached a conciliation agreement with the U.S. Department of Labor’s Office of Federal Contract Compliance Programs (OFCCP) to resolve pay discrimination allegations. Under the agreement, Pfizer will pay $2 million, including back pay and interest, as part of the settlement. This settlement comes after OFCCP’s compliance review of Pfizer’s practices during the period between 2015 and 2016, where it allegedly found evidence of pay discrimination against 86 women compared to their male counterparts.
Background and Allegationі
The probe by OFCCP uncovered disturbing findings of pay discrimination within Pfizer’s workforce. According to the agency, 86 female employees were consistently paid less than their male counterparts in comparable positions, violating federal guidelines and Executive Order 11246, which prohibits employment discrimination based on protected characteristics. The allegations highlight the need for further investigation and remedial actions to rectify the situation.
Pfizer’s response
Pfizer, in response to the allegations, expressed its deep commitment to equity for all employees. The company acknowledged its partnership with the Department of Labor (DOL) to ensure fair pay practices but denied modifying its compensation system. While the company maintained its innocence regarding any intentional discrimination, it recognized the importance of addressing the issue and taking steps to rectify any disparities that may exist.
Settlement details
Under the conciliation agreement, Pfizer will make a total payout of $2 million. This includes over $1.2 million in back pay to the affected female employees who were underpaid, along with more than $737,000 in interest. The substantial financial compensation aims to rectify the past discrepancies and provide restitution for the impacted employees. Furthermore, Pfizer has agreed to discontinue any discriminatory compensation practices immediately.
Actions required by Pfizer
To ensure fair and equitable compensation practices moving forward, Pfizer has committed to implementing comprehensive training programs. These programs will be designed to educate individuals involved in determining compensation for the affected job titles, promoting awareness of the importance of pay equity within the organization. By implementing these measures, Pfizer hopes to create a more inclusive and fair work environment for all its employees.
Pay Equity Enforcement Actions by the OFCCP
This settlement with Pfizer is part of a series of recent enforcement actions taken by the OFCCP to address pay discrimination. Under the Biden administration, OFCCP Director Jenny Yang has identified pay equity as a top focus for the agency in 2021. This indicates a renewed commitment to ensuring that federal contractors, like Pfizer, adhere to fair pay practices and proactively rectify any disparities that may exist.
Pfizer’s case joins the ranks of other prominent companies, such as JPMorgan Chase & Co. and Microsoft-owned LinkedIn, that have also entered into conciliation agreements with OFCCP. By holding these companies accountable for pay discrimination, OFCCP aims to create a significant shift towards fair compensation practices within the business community.
The $2 million settlement between Pfizer and the U.S. Department of Labor’s Office of Federal Contract Compliance Programs serves as a critical milestone in addressing pay discrimination allegations. With the implementation of the conciliation agreement, Pfizer will provide financial restitution to the affected female employees and undertake essential training programs. This case, along with other enforcement actions taken by OFCCP, highlights the firm commitment to achieving pay equity and eliminating discrimination in the workplace. Through such measures, it is hoped that companies will strive to uphold fair compensation practices and foster an inclusive environment for all employees, irrespective of their gender or other protected characteristics.